HT-29: Human Colorectal Adenocarcinoma Cell Line (ATCC HTB-38)

SK 809
Share

Description

HT-29 is a human colorectal adenocarcinoma cell line with epithelial morphology. These cells are sensitive to the chemotherapeutic drugs 5-fluorouracil and oxaliplatin, which are standard treatment options for colorectal cancer. In addition to being a xenograft tumor model for colorectal cancer, the HT-29 cell line is also used as an in-vitro model to study absorption, transport, and secretion by intestinal cells. Under standard culture conditions, these cells grow as a nonpolarized, undifferentiated multilayer. Altering culture conditions or treating the cells with various inducers, however, results in a differentiated and polarized morphology, characterized by the redistribution of membrane antigens and development of an apical brush-border membrane.

Source

This cell line was established in 1964 from the primary tumor of a 44-year-old Caucasian female with colorectal adenocarcinoma.

Inventors

Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
  • Cohen E at al. (1999) Induced differentiation in HT29, a human colon adenocarcinoma cell line. Journal of Cell Science 112: 2657-2666 (PubMed ID: 10413674)
  • Nautiyal J et al. (2011) Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. Journal of Molecular Signaling 6: 7 (PubMed ID: 21774804)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

  • Express License:  For internal research purposes by a for-profit entity:  1) Fill out MSK’s ATCC Express License, see here for links to the online fillable ATCC Express License, as well as a PDF version.  2) After execution by MSK, you will receive a signed copy, and can then place your order with ATCC. For detailed guidance on how to fill out this webform, see here. Please note:  In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to $10,000 must be made by credit card.
  • Commercial License: Contact MSK’s Tangible Materials team at [email protected].

For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, [email protected]

Stage of Development

Ready to use

Indications